Meloxicam was patented in 1977 and approved for medical use in the United States in 2000.[11][13] It was developed by Boehringer Ingelheim and is available as a generic medication.[11] In 2022, it was the 29th most commonly prescribed medication in the United States, with more than 18million prescriptions.[14][15] An intravenous version of meloxicam (Anjeso) was approved for medical use in the United States in February 2020.[16][12]
In October 2020, the US Food and Drug Administration (FDA) required the prescription drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[20][21] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[20][21]
Cardiovascular
Like other NSAIDs, its use is associated with an increased risk of cardiovascular events such as heart attack and stroke.[22] Although meloxicam inhibits formation of thromboxane A, it does not appear to do so at levels that would interfere with platelet function.[23][24] A pooled analysis of randomized, controlled studies of meloxicam therapy of up to 60 days duration found that meloxicam was associated with a statistically significantly lower number of thromboembolic complications than the NSAID diclofenac (0.2% versus 0.8% respectively) but a similar incidence of thromboembolic events to naproxen and piroxicam.[25]
People with hypertension, high cholesterol, or diabetes are at risk for cardiovascular side effects. People with family history of heart disease, heart attack, or stroke should tell their treating physician as the potential for serious cardiovascular side effects is significant.[26][27]
Gastrointestinal
NSAIDs cause an increase in the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. Elderly patients are at greater risk for serious gastrointestinal events.[28]
Meloxicam concentrations in synovial fluid range from 40% to 50% of those in plasma. The free fraction in synovial fluid is 2.5 times higher than in plasma, due to the lower albumin content in synovial fluid compared to plasma. The significance of this penetration is unknown,[28] but it may account for the fact that it performs exceptionally well in treatment of arthritis in animal models.[29]
Pharmacokinetics
Absorption
The bioavailability of meloxicam is decreased when administered orally compared to an equivalent IV bolus dose. Different oral formulations of meloxicam are not bioequivalent.[11] Use of oral meloxicam following a high-fat breakfast increases the mean peak drug levels by about 22%; however, the manufacturer does not make any specific meal recommendations. In addition, the use of antacids does not show pharmacokinetic interactions.[4] With chronic dosing, the time to maximum plasma concentration following oral administration is approximately 5–6 hours.[30]
Distribution
The mean volume of distribution of meloxicam is approximately 10 L. It is highly protein-bound, mainly to albumin.[24][30]
Metabolism
Meloxicam is extensively metabolized in the liver by the enzymes CYP2C9 and CYP3A4 (minor) into four inactive metabolites. Peroxidase activity is thought to be responsible for the other two remaining metabolites.[4][31]
Excretion
Meloxicam is predominantly excreted in the form of metabolites and occurs to equal extents in the urine and feces.[4] Traces of unchanged parent drug are found in urine and feces.[4] The mean elimination half-life ranges from 15 to 20 hours.[4]
Specific populations
The use of meloxicam is not recommended in people with peptic ulcer disease or increased gastrointestinal bleeding risk, including those over 75 years of age or those taking medications associated with bleeding risk.[32]
Adverse events are dose-dependent and associated with length of treatment.[32][4]
Depending on the animal species, each country or union of countries applies different guidelines or legal frameworks for the use of the drug, as well as different recorded side effects. The most common side effects in dogs include gastrointestinal irritation (vomiting, diarrhea, and ulceration).[33] As far as the perioperative administration is concerned, in healthy dogs given meloxicam, no perioperative adverse effects on the cardiovascular system have been reported at recommended dosages.[39] Perioperative administration of meloxicam to cats did not affect postoperative respiratory rate nor heart rate.[40]
Use of meloxicam in cats
The issue of using meloxicam in cats involves conflicting guidelines, differing legislation, and a narrow therapeutic safety margin that can easily turn the drug from cure to poison. More specifically:
US policy vs EU policy
The US Food and Drug Administration (FDA) approves the use of meloxicam in cats only in injectable form and only as a one-time injection given before surgery.[41][42] It does not approve meloxicam oral suspension for cats and it does not approve meloxicam spray for cats because after reviewing numerous reports of meloxicam side effects in cats, it has identified many cases of acute renal failure and death and has added the following boxed warning to the products' label: "Repeated use of meloxicam in cats has been associated with acute renal failure and death. Do not administer additional injectable or oral meloxicam to cats. See Contraindications, Warnings, and Precautions for detailed information."[43]
In contrast, in the European Union and other continents or countries, the use of the drug in cats is allowed with no such warning.[44][45] The product instruction leaflet for meloxicam for cats in the form of oral suspension 0.5 mg/ml states that: "Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy, and renal failure have occasionally been reported. These side effects are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal."[46]
Dosage and safety margin
The data sheets for meloxicam products for cats also state that: "Meloxicam has a narrow therapeutic safety margin in cats and clinical signs of overdose may be seen at relatively small overdose levels."[46] The dosage policy for meloxicam oral suspension products for cats as described in the data sheets defines the amount administered as proportional to body weight. There is no separate dosage guideline for overweight or obese cats. Similarly, there is no separate dosage instruction for elderly cats.
This information is important because, shifting attention briefly to the human medical field, where more studies have been conducted, there are medical opinions suggesting that the typical dosage of certain medications can lead to toxicity if factors such as obesity[47] or the patient’s age[48] are not taken into account.
Additional studies
Some additional information about giving meloxicam to cats from researchers is as follows: A peer-reviewed journal article cites NSAIDs, including meloxicam, as causing gastrointestinal upset and, at high doses, acute kidney injury and CNS signs such as seizures and comas in cats. It adds that cats have a low tolerance for NSAIDs.[49][50] Also, in another scientific journal there is talk of research according to which cats that received meloxicam had greater proteinuria at 6 months than cats that received placebo. It was concluded that meloxicam should be used with caution in cats with chronic kidney disease.[51]
Pharmacokinetics
In dogs, the absorption of meloxicam from the stomach is not affected by the presence of food,[52] with the peak concentration (Cmax) of meloxicam occurring in the blood 7–8 hours after administration.[52] The half-life of meloxicam is approximately 24 hours in dogs.[52] In the koala (Phascolarctos cinereus), very little meloxicam is absorbed into the blood after oral administration (that is, it has poor bioavailability).[53]
Legal status
United States
2003: Meloxicam was approved in the US for use in dogs for the management of pain and inflammation associated with osteoarthritis, as an oral (liquid) formulation of meloxicam.[54]
2004 (October): A formulation for use in cats was approved for use before surgery only.[56] This is an injectable meloxicam, indicated for as a single, one-time dose only, with specific and repeated warnings not to administer a second dose.[57]
2005 (January): The product insert added a warning in bold-face type: "Do not use in cats."[58]
2005: The FDA sent a Notice of Violation to the manufacturer for its promotional materials which included promotion of the drug for off-label use.[59]
2020 (February): A meloxicam injection was approved for use in the United States. Specifically, the FDA granted the approval of Anjeso to Baudax Bio.[12][60]
European Union
In the European Union, meloxicam is licensed for other anti-inflammatory benefits including relief from both acute and chronic pain in dogs. Meloxicam is also licensed for use in horses, to relieve the pain associated with musculoskeletal disorders.[61]
2006: The first generic meloxicam product was approved.[62]
2024 (January): EMA issued an 'Opinion'[63] on a change to this medicine's authorisation concerning the follow-up oral treatment after initial injectable administration in cats. This change remains as an 'Opinion', while the medication continues to be approved as usual.[64]
Other countries
As of June 2008[update], meloxicam is registered for long-term use in cats in Australia, New Zealand, and Canada.[65]
In the United Kingdom, meloxicam is licensed for use in cats, guinea pigs, horses, and livestock including pigs and cattle. [66]
^Stamm O, Latscha U, Janecek P, Campana A (January 1976). "Development of a special electrode for continuous subcutaneous pH measurement in the infant scalp". American Journal of Obstetrics and Gynecology. 124 (2): 193–195. doi:10.1016/S0002-9378(16)33297-5. PMID2012.
^Zeidan AZ, Al Sayed B, Bargaoui N, Djebbar M, Djennane M, Donald R, et al. (April 2013). "A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region". Pain Practice. 13 (4): 316–331. doi:10.1111/j.1533-2500.2012.00591.x. PMID22931375. S2CID205715393.
^ abGates BJ, Nguyen TT, Setter SM, Davies NM (October 2005). "Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety". Expert Opinion on Pharmacotherapy. 6 (12): 2117–2140. doi:10.1517/14656566.6.12.2117. PMID16197363. S2CID25512189. Meloxicam is extensively bound to plasma proteins (99.4%), primarily to albumin. Meloxicam has an apparent volume of distribution (Vd) 10 – 15 L in humans (0.1 – 0.2 L/kg) after oral administration and a mean volume of distribution at steady-state of 0.2 L/kg after intravenous administration." "None of the meloxicam treatment groups demonstrated inhibition of platelet aggregation to either arachidonic acid (AC) or adenosine diphosphate (ADP). However, there were no significant changes in the platelet count, prothrombin, and activated partial thromboplastin time in any of the meloxicam and indomethacin groups. Other crossover studies also confirmed that meloxicam 15 mg/day caused a major reduction of maximum thromboxane production, but no reduction in collagen- or AC-induced platelet aggregation.
^Singh G, Lanes S, Triadafilopoulos G (July 2004). "Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam". The American Journal of Medicine. 117 (2): 100–106. doi:10.1016/j.amjmed.2004.03.012. PMID15234645.
^ ab2019 American Geriatrics Society Beers Criteria Update Expert Panel (April 2019). "American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults". Journal of the American Geriatrics Society. 67 (4): 674–694. doi:10.1111/jgs.15767. PMID30693946. S2CID59338182.
^Boström IM, Nyman G, Hoppe A, Lord P (January 2006). "Effects of meloxicam on renal function in dogs with hypotension during anaesthesia". Veterinary Anaesthesia and Analgesia. 33 (1): 62–9. doi:10.1111/j.1467-2995.2005.00208.x. PMID16412133.
^ abcKhan SA, McLean MK (March 2012). "Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats". The Veterinary Clinics of North America. Small Animal Practice. 42 (2): 289–306, vi–vii. doi:10.1016/j.cvsm.2012.01.003. PMID22381180.
^"Client Information Sheet For Metacam (meloxicam) 1.5 mg/mL Oral Suspension"(PDF). U.S. Food and Drug Administration (FDA). January 2005. Archived from the original(PDF) on 15 November 2017. Metacam is a prescription non-steroidal anti-inflammatory drug (NSAID) that is used to control pain and inflammation (soreness) due to osteoarthritis in dogs. Osteoarthritis (OA) is a painful condition caused by "wear and tear" of cartilage and other parts of the joints that may result in the following changes or signs in your dog: Limping or lameness, decreased activity or exercise (reluctance to stand, climb stairs, jump or run, or difficulty in performing these activities), stiffness or decreased movement of joints. Metacam is given to dogs by mouth. Do not use Metacam Oral Suspension in cats. Acute kidney injury and death have been associated with the use of meloxicam in cats.
^Gaschen FP, Schaer M, eds. (2016). "Recent NSAID developments". Clinical medicine of the dog and cat (3rd ed.). CRC Press. ISBN9781482226065. Archived from the original on 1 September 2020. Retrieved 28 January 2020.
